Potential Role of Oral Anthracyclines in Older Patients with Cancer

Drugs & Aging ◽  
1994 ◽  
Vol 4 (5) ◽  
pp. 392-402 ◽  
Author(s):  
Wieslaw S. Lasota ◽  
Dominique L. de Valeriola ◽  
Martine J. Piccart
Keyword(s):  
Older Patients ◽  
Potential Role ◽  
Patients With Cancer

scholarly journals Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial

BMC Cancer ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Pierre Soubeyran ◽  
Catherine Terret ◽  
Carine Bellera ◽  
Franck Bonnetain ◽  
Olivier Saint Jean ◽  
...  
Keyword(s):  
Older Patients ◽  
Multicenter Trial ◽  
Phase Iii ◽  
Patients With Cancer ◽  
Geriatric Intervention

The Expanded Potential Role of Pharmacogenomics

2021 ◽  
Vol 36 (6) ◽  
pp. 270-272
Author(s):  
David F. Kisor
Keyword(s):  
Patient Care ◽  
Older Patients ◽  
Potential Role ◽  
Increased Sensitivity

The topic of phenoconversion was chosen for discussion in this editorial to add to the work presented by Cox and Marshall in this issue of The Senior Care Pharmacist. When considering the increased sensitivity that older patients have to medications, the inclusion of pharmacogenomics (PGx) information can be of great importance. Understanding the consequences of phenoconversion can further expand the role of PGx in patient care.

scholarly journals The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Kathleen M. Hagen ◽  
Shalina S. Ousman
Keyword(s):  
Immune Response ◽  
Immune Cells ◽  
Older Patients ◽  
Potential Role ◽  
Immune Cell ◽  
Chronic Inflammatory Demyelinating Polyradiculoneuropathy ◽  
Cell Populations ◽  
Relapsing Remitting ◽  
Progressive Course

AbstractChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) consists of various autoimmune subtypes in which the peripheral nervous system (PNS) is attacked. CIDP can follow a relapsing-remitting or progressive course where the resultant demyelination caused by immune cells (e.g., T cells, macrophages) and antibodies can lead to disability in patients. Importantly, the age of CIDP patients has a role in their symptomology and specific variants have been associated with differing ages of onset. Furthermore, older patients have a decreased frequency of functional recovery after CIDP insult. This may be related to perturbations in immune cell populations that could exacerbate the disease with increasing age. In the present review, the immune profile of typical CIDP will be discussed followed by inferences into the potential role of relevant aging immune cell populations. Atypical variants will also be briefly reviewed followed by an examination of the available studies on the immunology underlying them.

Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13)

2015 ◽  
Vol 6 (4) ◽  
pp. 272-279 ◽  
Author(s):  
Andrea Luciani ◽  
Laura Biganzoli ◽  
Giuseppe Colloca ◽  
Cristina Falci ◽  
Bruno Castagneto ◽  
...  
Keyword(s):  
Older Patients ◽  
Chemotherapy Toxicity ◽  
Patients With Cancer

scholarly journals The Potential Role of Cytokine Therapy for Fungal Infections in Patients with Cancer: Is Recovery from Neutropenia all that is Needed?

1998 ◽  
Vol 26 (6) ◽  
pp. 1270-1278 ◽  
Author(s):  
Libsen J. Rodriguez‐Adrian ◽  
Monica L. Grazziutti ◽  
John H. Rex ◽  
Elias J. Anaissie
Keyword(s):  
Potential Role ◽  
Fungal Infections ◽  
Cytokine Therapy ◽  
Patients With Cancer

scholarly journals Cancer and Aging: Two Tightly Interconnected Biological Processes

Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1400
Author(s):  
Lieze Berben ◽  
Giuseppe Floris ◽  
Hans Wildiers ◽  
Sigrid Hatse
Keyword(s):  
Older Patients ◽  
Current Knowledge ◽  
Geriatric Oncology ◽  
Individual Treatment ◽  
Treatment Regimens ◽  
Patients With Cancer ◽  
Increased Risk ◽  
The Impact

Age is one of the main risk factors of cancer; several biological changes linked with the aging process can explain this. As our population is progressively aging, the proportion of older patients with cancer is increasing significantly. Due to the heterogeneity of general health and functional status amongst older persons, treatment of cancer is a major challenge in this vulnerable population. Older patients often experience more side effects of anticancer treatments. Over-treatment should be avoided to ensure an optimal quality of life. On the other hand, under-treatment due to fear of toxicity is a frequent problem and can lead to an increased risk of relapse and worse survival. There is a delicate balance between benefits of therapy and risk of toxicity. Robust biomarkers that reflect the body’s biological age may aid in outlining optimal individual treatment regimens for older patients with cancer. In particular, the impact of age on systemic immunity and the tumor immune infiltrate should be considered, given the expanding role of immunotherapy in cancer treatment. In this review, we summarize current knowledge concerning the mechanistic connections between aging and cancer, as well as aging biomarkers that could be helpful in the field of geriatric oncology.

scholarly journals ADHFE1 is a correlative factor of patient survival in cancer

2021 ◽  
Vol 16 (1) ◽  
pp. 571-582
Author(s):  
Qi Chen ◽  
Qiyan Wu ◽  
Yaojun Peng
Keyword(s):  
Cell Cycle Regulation ◽  
Potential Role ◽  
Patient Survival ◽  
Regulatory Mechanisms ◽  
Biological Processes ◽  
Tissue Samples ◽  
Patients With Cancer ◽  
Patient Prognosis ◽  
Cycle Regulation

Abstract Alcohol dehydrogenase iron containing 1 (ADHFE1) encodes a hydroxyacid-oxoacid transhydrogenase participating in multiple biological processes. The role of ADHFE1 in cancer has not been fully uncovered. Herein, we performed data analysis to investigate the expression of ADHFE1 and the underlying regulatory mechanisms, its relationship with cancer patients’ survival, and the relevant pathways in cancer. A range of recognized, web-available databases and bioinformatics tools were used in this in silico study. We found that ADHFE1 was frequently downregulated and hypermethylated in various cancer cell lines and tissue samples. High expression of ADHFE1 was positively associated with favorable patient prognosis in breast, colon, and gastric cancers. Pathway analysis revealed its potential role in cancer-related biological processes, including energy metabolism, DNA replication, and cell cycle regulation. AHDFE1 mRNA expression and DNA methylation can potentially be used as diagnostic markers in cancer and might be of great value in predicting the survival of patients with cancer.

scholarly journals Hepcidin as a Predictor of Response to Epoetin Therapy in Anemic Cancer Patients

2009 ◽  
Vol 55 (7) ◽  
pp. 1354-1360 ◽  
Author(s):  
Lidia Ukarma ◽  
Hélène Johannes ◽  
Ulrich Beyer ◽  
Michel Zaug ◽  
Bruno Osterwalder ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Potential Role ◽  
Predictive Marker ◽  
Patients With Cancer ◽  
Pooled Data ◽  
Significant Difference ◽  
Serum Hepcidin ◽  
High Concentrations ◽  
Using Data

Abstract Background: Hepcidin is thought to be the central regulator of iron metabolism. Iron deficiency is associated with low hepcidin concentrations, and anemia in patients with cancer is associated with high concentrations of hepcidin. Study objectives: Our main objective was to assess the potential role of hepcidin for predicting response to epoetin therapy in anemic cancer patients. We also aimed to identify a cutoff value for hepcidin as a potential predictive marker for response to epoetin therapy. Methods: Using data from 525 anemic cancer patients enrolled in 5 studies, we assessed serum hepcidin concentrations in 408 of these patients at baseline and analyzed pooled data from the 408 patients. The analysis population was separated into 2 categories using a threshold hepcidin concentration of 13 nmol/L: low hepcidin (<13 nmol/L) and high hepcidin (≥13 nmol/L). Results: A significantly higher percentage of responders (defined as hemoglobin increase ≥10 g/L or ≥20 g/L from baseline) was observed in the low hepcidin group compared with the high hepcidin group (P = 0.04 for ≥10 g/L increase and P = 0.009 for ≥20 g/L from baseline). There was also a statistically significant difference between the 2 groups for hematopoietic response (hemoglobin rise at least once ≥20 g/L from baseline or at least once ≥120 g/L) to epoetin therapy (P = 0.0004). Conclusions: The results of this analysis suggest a potential role of hepcidin serum concentrations in predicting the response to epoetin therapy.

Sign in / Sign up

Export Citation Format

Share Document